blu-808
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 7, 2024 (NCT06948032)
Timeline
Indications
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06931405 | Phase 2 | May 28, 2025 | Blueprint Medicines Corporation |
| NCT06922448 | Phase 2 | Apr 14, 2025 | Blueprint Medicines Corporation |
| NCT06948032 | Phase 1 | Aug 7, 2024 | Blueprint Medicines Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blueprint Medicines Corporation | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1